Gide has advised EOS imaging, a pioneer in 2D and 3D orthopaedic medical imaging, on entering into a binding agreement with Fosun Pharmaceutical AG, an indirect subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., for an equity investment to be made by Fosun Pharmaceutical AG through the issuance of new EOS imaging shares.
Upon completion of the investment, EOS imaging will issue 3,446,649 new shares to be subscribed by Fosun Pharmaceutical AG, for a price per share of €4.37, incl. issue premium, amounting to a total of approximately €15.1m. Fosun Pharma, through Fosun Pharmaceutical AG, will hold approximately 13.2% of existing shares and voting rights, thus becoming the largest shareholder of EOS imaging.
The completion of the investment is subject to approvals from the Chinese government authorities and the French financial markets authority (AMF) on a prospectus consisting of the Document de Référence filed with the AMF on 27 April 2018 under number D.18-0439, and a Note d'Opération that will include a summary of the prospectus.
Gide's team comprised partner Anne Tolila with associate Elise Bernard on corporate aspects.